Allogene Therapeutics (ALLO) Accumulated Expenses (2018 - 2026)

Allogene Therapeutics has reported Accumulated Expenses for 9 years, with the latest figure at $23.4 million in Q1 2026.

• Quarterly Accumulated Expenses fell 6.28% year-over-year to $23.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.4 million (down 6.28% YoY) and the FY2025 annual result came in at $28.2 million, down 6.26% from the prior year.
• Accumulated Expenses eased to $23.4 million in Q1 2026 per ALLO's latest filing, from $28.2 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $44.6 million in Q1 2023 and troughed at $23.4 million in Q1 2026.
• A 5-year average of $31.1 million and a median of $28.2 million in 2025 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses soared 60.73% in 2023, then sank 44.94% in 2024.
• Over 5 years, Accumulated Expenses stood at $39.7 million in 2022, then retreated by 21.54% to $31.2 million in 2023, then dropped by 3.38% to $30.1 million in 2024, then dropped by 6.26% to $28.2 million in 2025, then dropped by 17.16% to $23.4 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $23.4 million, $28.2 million, and $28.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.